Immune checkpoint inhibitors (ICIs) targeting the programmed death 1 (PD‐1)/PD ligand 1 (PD‐L1) pathway have revolutionized the treatment of advanced NSCLC; however, the observed OS benefit with second‐line ICI monotherapy over docetaxel in patients with NSCLC has failed to extend to EGFR‐mutated patients.17, 18. This evidence concerns the gene EGFR and non-small cell lung carcinoma.